Is Prostate Cancer Hereditary? What Men and Their Families Need to Know

By Amanda Shrewsbury, MS, CGC

Unfortunately, for many men and their families, the words "prostate cancer" are heard more and more often nowadays. Despite increasing rates of diagnosis, most men are unaware of whether their prostate cancer could be hereditary.

About one in eight men in the United States will be diagnosed with prostate cancer at some point in his lifetime, and the number of new diagnoses each year continues to climb. Most of those cases are not driven by an inherited gene change. But a meaningful share are. Estimates suggest that 10–15% of men with prostate cancer carry a pathogenic variant (a DNA change that increases cancer risk) in a gene that played a role in their disease, and the share is even higher among men diagnosed at younger ages or with more aggressive disease (Pritchard et al., 2016; NCCN, 2026).

Whether you've recently been diagnosed and are considering testing as part of your treatment plan, or your father or brother had prostate cancer and you're trying to understand what that means for you, this post walks through what's known, what testing can tell you, and what to do next.

Is Prostate Cancer Hereditary?

Yes, sometimes. Most prostate cancer is not inherited. It develops as a result of aging, environmental factors, and a degree of chance. But for an important minority of men, an inherited gene change is part of the picture, and identifying that gene change can shift everything from how the cancer is treated to how the rest of the family is screened.

There are two ways genetics tends to show up in a prostate cancer story. The first is a single high-penetrance gene change, meaning a variant in a gene that on its own confers a substantially elevated lifetime cancer risk, like a pathogenic variant in BRCA2. These variants meaningfully raise the lifetime risk of prostate cancer and often shift the cancer toward earlier onset and more aggressive behavior. The second is family clustering without a single identified gene, where multiple relatives have had prostate cancer but the underlying genetic explanation isn't yet known. Both scenarios are reasons to talk to a genetic counselor.

What Genes Are Linked to Hereditary Prostate Cancer?

A handful of genes are well-established as contributors to prostate cancer risk. Most are involved in homologous recombination repair (HRR), one of the cell's main systems for fixing damaged DNA. When these genes don't work properly, cells lose their ability to repair certain kinds of DNA damage, and cancer becomes more likely.

BRCA2 has the strongest and most well-studied association. Men with a BRCA2 pathogenic variant face a substantially elevated lifetime risk of prostate cancer, with prospective UK data putting the absolute risk at roughly 27% by age 75 and 60% by age 85, compared to about 16% in the general population (Nyberg et al., 2020). BRCA2-related prostate cancer also tends to be diagnosed earlier and to behave more aggressively. (For more on what BRCA1 and BRCA2 do generally, see BRCA1 and BRCA2 Explained.)

BRCA1 is associated with a more modest but still real increase in prostate cancer risk. The effect is weaker than for BRCA2, and most pronounced at younger ages.

HOXB13 is a moderate-penetrance gene with a recurring variant called G84E, particularly common in men of Nordic and Northern European ancestry. Population-based data show that carriers face roughly a 33% cumulative risk of prostate cancer by age 80, compared to about 12% in noncarriers (Karlsson et al., 2014).

ATM, CHEK2, and PALB2 are also part of the DNA repair pathway and carry smaller but established increases in prostate cancer risk. Their role is becoming more important clinically because some of the targeted therapies for advanced prostate cancer respond to alterations in these genes.

Mismatch repair gene variants (MLH1, MSH2, MSH6, PMS2, EPCAM), the genes responsible for Lynch syndrome, are also associated with a modest increase in prostate cancer risk, particularly in men with MSH2 variants.

These genes are typically tested together on a multigene panel rather than one at a time, since the same panel can answer questions about prostate cancer risk along with risks for breast, ovarian, pancreatic, colorectal, and other cancers.

What Family History Suggests Hereditary Prostate Cancer?

Some patterns in a family tree raise the likelihood that prostate cancer in your family has a hereditary component. Even one of the following is reason enough to consider a conversation with a genetic counselor:

A relative diagnosed with prostate cancer at a young age, particularly before 60. Younger-onset prostate cancer is more likely to be linked to an inherited gene change.

Multiple relatives on the same side of the family with prostate cancer. The clustering matters more than the total number, because hereditary syndromes are passed down through a single line of inheritance.

A family history of related cancers on the same side. BRCA2-related prostate cancer often shows up alongside breast, ovarian, and pancreatic cancers in the same family, so cancer patterns that span more than one cancer type are worth paying attention to.

A relative with metastatic, high-Gleason, or otherwise aggressive prostate cancer. Current NCCN guidelines recommend germline genetic testing for any man diagnosed with metastatic prostate cancer, regardless of family history (NCCN, 2026).

Ashkenazi Jewish ancestry. About 1 in 40 people of Ashkenazi Jewish descent carries a BRCA1 or BRCA2 pathogenic variant, compared to roughly 1 in 400 in the general population.

A family member who has already tested positive for a hereditary cancer variant. If there's a known variant in the family, cascade testing gives a clear yes-or-no answer about whether you carry it.

(For a fuller discussion of family history red flags across all cancer types, see What Your Family Tree Might Be Telling You About Cancer Risk.)

Should I Get Genetic Testing for Prostate Cancer?

Genetic testing for prostate cancer serves two distinct purposes, depending on where you're starting from.

If you've been diagnosed with prostate cancer, testing can directly inform your treatment plan. NCCN guidelines recommend germline genetic testing for any man with metastatic prostate cancer, high-risk localized prostate cancer, regional disease, intraductal or cribriform histology, or a family history that suggests hereditary risk. The list of qualifying scenarios has expanded considerably over the last several guideline updates, so even if you didn't qualify a few years ago, you may qualify now (NCCN, 2026).

If you haven't been diagnosed with prostate cancer, testing is generally appropriate when your family history meets specific criteria. These include having a close relative with a known hereditary cancer variant, multiple relatives on one side of the family with prostate cancer, a relative diagnosed before 60, a family history of breast, ovarian, or pancreatic cancer alongside prostate cancer, or Ashkenazi Jewish ancestry combined with any cancer family history.

In both scenarios, the right starting point is a conversation with a genetic counselor. They'll review your personal and family history, decide whether testing makes sense, walk through what testing can and cannot tell you, and help you understand what any result would mean for your care. (For what to expect from that conversation, see What Actually Happens During a Genetic Counseling Appointment.)

How Does Genetic Testing Affect Prostate Cancer Treatment?

This is one of the biggest reasons genetic testing has become so important for men diagnosed with prostate cancer. A positive result can change which treatments work best for the cancer you already have, in addition to telling you something about your future risk and your family's risk.

The most established example is PARP inhibitor therapy. PARP inhibitors are a class of drugs that target a specific weakness in cancer cells with HRR pathway alterations. For men with metastatic castration-resistant prostate cancer (mCRPC) and a BRCA1, BRCA2, or other HRR gene variant, PARP inhibitors have meaningfully changed survival outcomes. Several are now FDA-approved for this use, including olaparib (alone and in combination with abiraterone), rucaparib, talazoparib in combination with enzalutamide, and niraparib in combination with abiraterone. More recently, niraparib plus abiraterone has been approved for BRCA2-mutated metastatic castration-sensitive prostate cancer, moving these therapies earlier in the treatment course (FDA, 2025).

For men with Lynch syndrome and prostate cancer, the picture is different but also actionable. Lynch-associated prostate tumors often have features (microsatellite instability or mismatch repair deficiency) that make them more responsive to immune checkpoint inhibitor therapies.

Genetic test results are also increasingly used to inform clinical trial eligibility, since many of the most promising new prostate cancer trials enroll based on specific genetic features.

For a man with prostate cancer, especially advanced or aggressive prostate cancer, a genetic test result can directly shape what comes next. (For a deeper explanation of what positive, negative, and uncertain results mean, see What Your Genetic Test Results Actually Mean.)

How Is Screening Different for Men at Hereditary Risk?

Men with certain hereditary cancer variants benefit from earlier and more frequent prostate cancer screening, because their cancers tend to develop sooner and progress faster than average.

For context, the American Cancer Society recommends that men at average risk start a conversation with their provider about PSA screening at age 50. The recommended start age moves earlier for men at higher baseline risk: 45 for African American men or those with a first-degree relative diagnosed before 65, and 40 for men with more than one first-degree relative diagnosed at an early age (American Cancer Society, 2024).

For BRCA2 carriers, NCCN recommends starting PSA testing at age 40, with consideration of annual screening intervals (NCCN, 2026). The same approach is reasonable for BRCA1 carriers, although the underlying risk is somewhat lower. Men with HOXB13 G84E and HRR pathway variants should also consider earlier screening, with timing and frequency individualized based on family history and gene-specific risk.

This earlier screening is more than a precaution. The IMPACT study, an international prospective trial of PSA screening in men with BRCA1 and BRCA2 variants, found that BRCA2 carriers screened with annual PSA had higher detection rates of clinically significant prostate cancer, were diagnosed at younger ages, and were more likely to have aggressive disease at diagnosis (Page et al., 2019).

In practice, what this means is that knowing your hereditary risk gives your urologist or primary care provider the information they need to start screening when it's most likely to catch cancer early, when it's most treatable.

What Does My Result Mean for My Family?

If you test positive for a hereditary cancer variant, your result has real implications for your relatives. Each of your first-degree relatives (parents, siblings, and children) may have up to a 50% chance of carrying the same variant.

This is where cascade testing comes in. Once a specific variant is identified in your family, your relatives can be tested for that exact variant. The test is straightforward, typically insurance-covered, and gives a clear yes-or-no answer.

One thing worth saying clearly: BRCA and other hereditary cancer variants affect both men and women, and they're equally likely to be passed to a son or a daughter. For men reading this, that means your daughters, sisters, and other female relatives have meaningful breast and ovarian cancer risk implications from your result. For women reading this whose male relatives might benefit from testing, your brothers, fathers, sons, uncles, and nephews need to know too. (For more on why men's hereditary cancer risk has been historically under-recognized, see Men and Hereditary Cancer.)

Your genetic counselor will give you a family letter designed to be shared with relatives, explaining what was found and what their next steps could look like. You don't have to carry the full weight of the explanation yourself.

You Have Options

A hereditary cancer diagnosis can feel like one more thing to deal with on top of everything else, especially if you're already navigating a cancer diagnosis. But the information you get from genetic testing for prostate cancer is some of the most actionable information in cancer care today. Earlier screening catches cancer at more treatable stages, and targeted therapies like PARP inhibitors are extending lives in ways that weren't possible a decade ago. Cascade testing gives your family the chance to take their own steps before something develops.

As prostate cancer shows up in more and more families, understanding the role of genetics becomes increasingly important.

If you're navigating a recent diagnosis, a concerning family history, or just want a clearer picture of where you stand, a board-certified genetic counselor who specializes in hereditary cancer can help you sort through it.

Want to learn if your family history patterns suggest hereditary cancer risk? Download our free guide: 5 Signs Your Family History May Indicate Hereditary Cancer Risk.

Have a question? Reach out anytime:

Email: hello@clearpathgenetics.com
Text or call: +1 (720) 799-0730

References

American Cancer Society. (2024). American Cancer Society recommendations for prostate cancer early detection. https://www.cancer.org/cancer/types/prostate-cancer/detection-diagnosis-staging/acs-recommendations.html

Karlsson, R., Aly, M., Clements, M., Zheng, L., Adolfsson, J., Xu, J., Grönberg, H., & Wiklund, F. (2014). A population-based assessment of germline HOXB13 G84E mutation and prostate cancer risk. European Urology, 65(1), 169–176. https://doi.org/10.1016/j.eururo.2012.07.027

National Comprehensive Cancer Network. (2026). Genetic/familial high-risk assessment: Breast, ovarian, pancreatic, and prostate (Version 3.2026). https://www.nccn.org

National Comprehensive Cancer Network. (2026). Prostate cancer early detection (Version 2.2026). https://www.nccn.org

Nyberg, T., Frost, D., Barrowdale, D., Evans, D. G., Bancroft, E., Adlard, J., Ahmed, M., Barwell, J., Brady, A. F., Brewer, C., Cook, J., Davidson, R., Donaldson, A., Eason, J., Gregory, H., Henderson, A., Izatt, L., Kennedy, M. J., Miller, C., … Antoniou, A. C. (2020). Prostate cancer risks for male BRCA1 and BRCA2 mutation carriers: A prospective cohort study. European Urology, 77(1), 24–35. https://doi.org/10.1016/j.eururo.2019.08.025

Page, E. C., Bancroft, E. K., Brook, M. N., Assel, M., Hassan Al Battat, M., Thomas, S., Taylor, N., Chamberlain, A., Pope, J., Raghallaigh, H. N., Evans, D. G., Rothwell, J., Maehle, L., Grindedal, E. M., James, P., Mascarenhas, L., McKinley, J., Side, L., Thomas, T., … Eeles, R. A. (2019). Interim results from the IMPACT study: Evidence for prostate-specific antigen screening in BRCA2 mutation carriers. European Urology, 76(6), 831–842. https://doi.org/10.1016/j.eururo.2019.08.019

Pritchard, C. C., Mateo, J., Walsh, M. F., De Sarkar, N., Abida, W., Beltran, H., Garofalo, A., Gulati, R., Carreira, S., Eeles, R., Elemento, O., Rubin, M. A., Robinson, D., Lonigro, R., Hussain, M., Chinnaiyan, A., Vinson, J., Filipenko, J., Garraway, L., … Nelson, P. S. (2016). Inherited DNA-repair gene mutations in men with metastatic prostate cancer. New England Journal of Medicine, 375(5), 443–453. https://doi.org/10.1056/NEJMoa1603144

U.S. Food and Drug Administration. (2025). FDA approves niraparib and abiraterone acetate with prednisone for BRCA-mutated metastatic castration-sensitive prostate cancer. https://www.fda.gov

---